Ketadex nasal spray: product information article
Updated: Feb 22
Intranasal administration offers an alternative route for systemically acting drugs, especially low molecular weight, lipophilic and potent drugs with high first-pass metabolism. It’s well recognized that nasal bioavailability is optimum with atomized volumes less than 100 microlitres (0.1ml), available ampoule content therefore has limited nasal residence time, absorption and bioavailability due to excess volume that drains into the throat and is swallowed. Ketadex nasal spray offers additive effects of sedation, analgesia, bronchodilation with nasal decongestion and dilation of cutaneous veins for cannulation. Opposing side effects produce dry mouth, reduced secretions and cardiovascular stability. A wide margin of safety is predicted because both ketamine and dexmedetomidine are devoid of respiratory depressant effects. We present an easy to administer nasal spray, concentrated (3.75x) ketamine and dexmedetomidine solution to produce reliable sedation and analgesia with minimal adverse effects due to favourable pharmacokinetic and pharmacodynamic interactions.